Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Cahn

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Diabetes, Obesity & Metabolism|February 10, 2017
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome studyAvivit Cahn, Ofri Mosenzon, Deepak L Bhatt, et al.
Emerging Infectious Diseases|November 7, 2009
Imported melioidosis, Israel, 2008Avivit Cahn, Benjamin Koslowsky, Ran Nir-Paz, et al.
Diabetes Care|September 12, 2015
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Cheryl Wei, Jaime Davidson, et al.
Diabetes Care|December 3, 2017
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic DiseaseBrian A Bergmark, Deepak L Bhatt, Eugene Braunwald, et al.
Journal of Diabetes and Its Complications|June 13, 2025
Clinical outcomes of patients with Polyvascular disease admitted with an acute diabetic foot ulcerNitzan Tal, Isca Hershkowitz, Kobi Gorin, et al.
Journal of Diabetes and Its Complications|July 15, 2026
Ethnic disparities in mortality following hospitalization for diabetic foot ulcerOmer Hamtzany, Tal Sigawi, Ariel Kenig, et al.
Circulation|August 1, 2019
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 TrialBrian A Bergmark, Deepak L Bhatt, Darren K McGuire, et al.
Clinical Chemistry|April 17, 2019
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Diabetes, Obesity & Metabolism|December 28, 2020
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trialPhil McEwan, Angharad R Morgan, Rebecca Boyce, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Diabetes, Obesity & Metabolism|February 10, 2017
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome studyAvivit Cahn, Ofri Mosenzon, Deepak L Bhatt, et al.
Emerging Infectious Diseases|November 7, 2009
Imported melioidosis, Israel, 2008Avivit Cahn, Benjamin Koslowsky, Ran Nir-Paz, et al.
Diabetes Care|September 12, 2015
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Cheryl Wei, Jaime Davidson, et al.
Diabetes Care|December 3, 2017
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic DiseaseBrian A Bergmark, Deepak L Bhatt, Eugene Braunwald, et al.
Journal of Diabetes and Its Complications|June 13, 2025
Clinical outcomes of patients with Polyvascular disease admitted with an acute diabetic foot ulcerNitzan Tal, Isca Hershkowitz, Kobi Gorin, et al.
Journal of Diabetes and Its Complications|July 15, 2026
Ethnic disparities in mortality following hospitalization for diabetic foot ulcerOmer Hamtzany, Tal Sigawi, Ariel Kenig, et al.
Circulation|August 1, 2019
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 TrialBrian A Bergmark, Deepak L Bhatt, Darren K McGuire, et al.
Clinical Chemistry|April 17, 2019
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Diabetes, Obesity & Metabolism|December 28, 2020
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trialPhil McEwan, Angharad R Morgan, Rebecca Boyce, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
Pageof 10